Triple-Negative Breast Carcinoma — Trials

Triple-Negative Breast Carcinoma — Trials · CancerIndex

Clinical trials

Registered studies

950 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 417
Recruiting: 234
Ph III recruiting: 22
Growth YoY: +2.4%
Industry share: 31%
Top sponsor: Fudan University
Termination share: 47.1%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (168)

clinicaltrialsPublishedShowing 1–6 of 6 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT04251533	Study Assessing the Efficacy and Safety of Alpelisib + Nab-paclitaxel in Subjects With Advanced TNBC Who Carry Either a PIK3CA Mutation or Have PTEN Loss(EPIK-B3)	terminated	Phase 3	137	Novartis PharmaceuticalsINDUSTRY	30	Sep 10, 2026	clinicaltrials
NCT03498716	A Study Comparing Atezolizumab (Anti PD-L1 Antibody) In Combination With Adjuvant Anthracycline/Taxane-Based Chemotherapy Versus Chemotherapy Alone In Patients With Operable Triple-Negative Breast Cancer(IMpassion030)	terminated	Phase 3	2,199	Hoffmann-La Roche